Pharmaceutical

Xyphos and Kelonia link for immuno-oncology drug development

Xyphos Biosciences has entered an agreement with Kelonia Therapeutics to develop immuno-oncology therapeutics for $875m.

Feb 16, 2024 - 18:00
Xyphos and Kelonia link for immuno-oncology drug development
Xyphos Biosciences has entered an agreement with Kelonia Therapeutics to develop immuno-oncology therapeutics for $875m.
Read the original article

Tags:

Previous Article

FDA grants orphan drug status to Ionis’ olezarsen for FCS treatment

Next Article

GSK concludes Aiolos Bio acquisition for $1.4bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The new fertility technology IVG is supposed to change everything. Don’t count on it yet

Opinion: The new fertility technology IVG is supposed t...

Oct 2, 2023

Roche relaunches refillable wet AMD implant two years after recall

Roche relaunches refillable wet AMD implant two years a...

Jul 10, 2024

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria drug

FDA grants RPDD to META Pharmaceuticals’ hyperoxaluria ...

Aug 7, 2024